“A Smart Approach to Accelerate Market Entry”
Rare diseases affect only a small number of patients and offer limited treatment options. Developing orphan drugs for these conditions carries not only immense social value but also strategic importance. However, the development process – including clinical trials – entails different regulatory frameworks and strategic considerations compared to common new drugs. In fact, of an estimated 7,000 rare diseases worldwide, over 95% still lack an approved treatment, underscoring the vast unmet need. Governments around the globe have introduced various incentives to spur orphan drug development, leading to an explosion of progress over the past few decades. For example, in the United States, since the Orphan Drug Act of 1983, the number of orphan drug designations in the 2010s soared to more than four times the number in the 1990s. This article outlines the must-know regulatory requirements and effective development strategies for pharmaceutical and biotech professionals planning orphan drug clinical trials.
What Is an Orphan Drug?
Each country sets its own population-based criteria to define a rare disease drug, or “orphan drug.” Generally, an orphan drug targets a very serious condition that affects a tiny patient population. For example, the defining thresholds include:
- South Korea: A drug for a disease affecting 20,000 or fewer patients, or for a disease with such low development potential that government support is deemed necessary.
- United States (FDA): A drug for a disease affecting 200,000 or fewer patients.
- European Union (EMA): A drug intended for a disease affecting no more than 5 patients per 10,000 people in the EU population.
Despite variations in legal definitions, all refer to treatments for severe illnesses with very small patient groups. Regulators in each region offer dedicated designation programs and incentives to encourage the development of these medicines.
Unique Regulatory Considerations
Orphan Drug Designation
Obtaining official Orphan Drug designation for a drug candidate unlocks valuable incentives for the developer. These typically include:
- USA (FDA): 7-year market exclusivity upon approval under the Orphan Drug Act, up to 25% tax credits on clinical trial costs, and waiver of FDA application fees (PDUFA fees).
- EU (EMA): 10-year market exclusivity, reduced fees for marketing authorization and scientific advice, and protocol assistance with trial design.
- South Korea (MFDS): Priority review designation (faster review timelines), partial funding support for development costs, and streamlined import procedures for trial materials.
By conferring special legal status and incentives, governments actively encourage orphan drug development. If a new drug candidate meets the criteria for orphan designation, it is advantageous for the developer to secure that status as early as possible.
Flexibility in Clinical Trial Design
Given the reality of extremely small patient pools in rare diseases, regulators tend to allow greater flexibility in trial design. When recruiting a control group is infeasible, developers can use a single-arm trial or an external control using historical data. Adaptive trial designs are also actively recommended. Regulatory decisions place more weight on clinical relevance than on strict statistical significance. In practice, this means that if an orphan drug trial can demonstrate meaningful improvement in even a few patients, approval may be possible despite a smaller data set or only modest statistical power.
Use of Real-World Evidence (RWE)
In recent years, regulators have increasingly embraced real-world evidence (RWE) – analyses of real-world patient data – in reviewing orphan drugs. Traditional randomized trials often struggle to enroll enough patients for rare conditions, making it hard to gather sufficient evidence. Agencies like the FDA are broadening acceptance of RWE as valid support for approval; for example, accepting non-invasive biomarkers in lieu of invasive liver biopsies in NASH (fatty liver disease) drug trials. Sponsors are encouraged to supplement submissions with patient registry data or real-world case reports, and even data from patient advocacy groups and clinical case studies are being considered valuable evidence. Maximizing the use of real-world clinical data has become a key strategy to demonstrate the efficacy and safety of new treatments for rare diseases.
Orphan Drug Clinical Development Strategies
Engage Regulators Early
In orphan drug development, close coordination with regulatory authorities from the outset is often the key to success. Early consultations – such as Pre-IND meetings in the U.S. or Scientific Advice meetings in other regions – help ensure that your clinical trial design aligns with regulatory expectations. If the drug is highly innovative, developers should also consider pursuing available expedited programs (e.g. Fast Track or Breakthrough Therapy designation in the U.S.) in addition to orphan designation. By engaging proactively with regulators in the early stages, sponsors can reduce trial-and-error later and pave the way for a smoother review process.
Diversify Patient Recruitment Channels
One of the greatest challenges in rare disease trials is recruiting enough patients. Over 80% of clinical trials globally face enrollment delays, and for rare diseases this challenge is magnified. Creative, multi-pronged recruitment strategies are essential. Collaborate with patient advocacy groups and online communities for the disease, leverage patient registries at major hospitals, and if needed, set up a multi-country clinical network to cast a wider net.
South Korea is an excellent example of a country that can enhance global recruitment. South Korea is a major clinical trial hub, ranking 6th in the world by clinical trial volume (conducting roughly 3.5% of all global trials). Seoul, in fact, has been the top city globally for number of clinical trials conducted for seven consecutive years (2017–2023). By tapping into such a robust clinical research environment through international trial sites – for instance, including South Korea in a multi-national trial – developers can greatly expand the patient pool and accelerate enrollment.
Strategic Use of Nonclinical Data
Rare disease drug developers typically face limited time and budget, so they must prepare nonclinical (preclinical) data strategically and efficiently. Wherever possible, leverage existing information to streamline your studies. For example, utilize data from already-approved drugs with similar mechanisms, or employ toxicity prediction models based on the structural features of the molecule, to optimize the scope of new animal studies. Through early consultation with regulators, sponsors may obtain waivers for unnecessary preclinical tests, focusing resources only on studies that are absolutely required. Especially in rare diseases – where appropriate animal models may be hard to find – it’s important to use alternative methods or literature evidence to scientifically justify your approach. The goal is to maximize scientific validity while minimizing redundant experiments.
Collaborate with an Experienced CRO
Rare disease trials are highly specialized and complex. Partnering with a Contract Research Organization (CRO) that has extensive experience in rare disease studies is widely regarded as a critical success factor. In particular, working with a South Korean CRO that is well-versed in both domestic and international regulatory procedures and has a track record in rare disease projects can be hugely beneficial. Such a partner helps overcome language and cultural barriers and makes full use of Korea’s advanced clinical trial infrastructure. Indeed, even small biotech startups with limited funds and manpower have shown that by strategically leveraging a skilled CRO, they can efficiently achieve successful development with limited resources. A professional CRO can support the entire trial process – from project management and regulatory filings to data management – allowing the sponsor to focus on core R&D. In short, a trustworthy, expert CRO partnership enables sponsors to improve the quality and speed of trial execution, which is especially vital in rare disease development.
Conclusion
Developing an orphan drug is a high-stakes endeavor that demands both social responsibility and business strategy. For a successful clinical development, several factors are key: close collaboration with regulators from the early stages, a strategic and flexible trial design, a broad global patient recruitment network, and a reliable specialist CRO partnership. By fully leveraging each country’s incentives and flexible regulatory provisions, and by applying creative approaches to make the most of limited data, one can nurture a small spark of hope into a major medical breakthrough.
About Intoinworld
Your People-First Clinical Trial Partner
“From person to person, delivering the value of clinical research.”
Intoinworld aims to be a bridge of trust that safely delivers the value of medicine to people. With a people-centered mindset and execution, we grow together with our clients as a true partner. Established in 2015 as a Contract Research Organization, Intoinworld has conducted clinical trials across all areas of research – including pharmaceuticals, biotechnology, medical devices, Investigator-Initiated Trials (IIT), and Observational Studies (OS). We have the expertise and execution capabilities to manage end-to-end clinical trials from Phase I to Phase III, as well as post-marketing surveillance (PMS).
Our dedicated teams of specialists in each department (Clinical Operations, Data Management, Statistics, Regulatory Affairs, etc.) ensure accurate and reliable results in compliance with domestic and international regulations. Please refer to our company introduction brochure for more details, and feel free to contact us anytime for collaboration or consultation. Intoinworld will be a reliable partner for the success of your clinical trial project.
If you are looking for ways to reduce clinical trial costs, we encourage you to request a quote from Intoinworld to receive a tailored consultation. And if you don’t want to miss the latest pharma/biotech industry trends and clinical trial insights, consider subscribing to Intoinworld’s newsletter to get valuable information on a regular basis.
Frequently Asked Questions (FAQ)
Q1. What is the difference between orphan drug clinical trials and regular new drug trials?
Orphan drug trials involve far fewer patients, which allows much greater flexibility in trial design. For example, if it is hard to include a control arm, the trial can proceed as a single-arm study or use historical patient data as an external control. If the trial demonstrates clear clinical benefit, regulators may grant approval even if the results are not statistically robust. Regulators also relax some requirements: sponsors can submit real-world evidence from actual clinical practice as supporting data, which is generally not the case for regular new drugs. On the other hand, because eligible patients are so scarce, patient recruitment requires extra attention, and developers need to coordinate closely with authorities from the early stages to craft a sound development strategy.
Q2. What benefits are provided if a drug receives orphan designation?
Orphan designation programs in each country grant a range of incentives like market exclusivity and financial support. For instance, in the U.S., the FDA awards 7-year market exclusivity for the approved indication, along with clinical trial tax credits and a waiver of application fees. In Europe, the EMA provides 10-year exclusivity plus reductions in approval and consultation fees. In South Korea, the MFDS offers measures such as priority review (to shorten approval time) and R&D grant programs. These incentives significantly enhance the appeal of investing in rare disease drug development.
Q3. Why collaborate with a Korean CRO for rare disease drug development?
South Korea’s clinical trial environment is among the best in the world. Partnering with a Korean CRO means you can tap into the country’s extensive clinical infrastructure. South Korea conducts about 3.5% of all clinical trials globally, and Seoul has been the number-one city for clinical trial count worldwide, reflecting superb patient recruitment and hospital networks. Korean CROs are highly experienced in managing multi-national trials and are experts in regulatory processes not only for the MFDS (Ministry of Food and Drug Safety) but also for the FDA, EMA, and other authorities. Therefore, having a Korean CRO as a partner can boost the quality and speed of your trial operations. It also allows you to communicate seamlessly with local investigators and patients without language or time-zone barriers, ultimately improving the chances of success for your orphan drug development project.